linjc16/ctgov huggingface dataset:
Novel Prognostic Markers in Renal Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.

Detailed Description
-----------------
Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.

Official Title
-----------------
Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples

Conditions
-----------------
Renal Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The presence of histologically proven renal cell cancer The availability of paraffin embedded tissue Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act) Exclusion Criteria: Absence of histological tissue Absence of consent to study tissue after January 2006
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumour tissue, renal cell carcinoma<br>> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biomarkers, Prognosis response to treatment, Renal cancer
Familial Clustering of Vitamin D Deficiency Via Shared Environment: The Korean National Health And Nutrition Examination Survey 2008-2012

Study Overview
=================
Brief Summary
-----------------
Vitamin D deficiency is a modifiable risk factor for poor bone health. Familial correlation of serum 25-hydroxyvitamin D concentration (25(OH)D) was reported in twin- or family-based studies, mostly from Caucasian parent-offspring pairs. However, data on the familial association of 25(OH)D in extended family structure and the relative contribution of genetic and shared environmental factors on serum 25(OH)D level are limited in Asian populations. In this study, the investigators aimed to assess the relative contribution of additive genetic and environmental components on serum 25(OH)D level by variance components method in a nationwide family-based cohort. Further, the investigators will evaluate the association of vitamin D status of index individual with prevalent vitamin D deficiency of each family member including spouse, offspring, sibling, and grand-offspring. Additive influences of paternal and maternal vitamin D status on offspring will be also investigated.

Detailed Description
-----------------
From the Korean National Health and Nutritional Examination Survey (KNHANES) conducted between 2008 and 2012, familial correlations for 25(OH)D will be estimated in different types of family relation pairs in 28551 subjects from 10882 families. The relative contribution of additive genetic and shared or individual environmental factors for variance of 25(OH)D level will be calculated using variance component method. Interactions between paternal and maternal vitamin D status for 25(OH)D level of offspring will be evaluated.

Official Title
-----------------
Familial Clustering of Vitamin D Deficiency Via Shared Environment: The Korean National Health And Nutrition Examination Survey 2008-2012

Conditions
-----------------
Vitamin D Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: KNHANES(Korean National Health and Nutrition Examination Survey) 2008-2012 participants Exclusion Criteria: missing value on 25-hydroxyvitamin D levels data on another household member was unavailable the precise family relationship between the subjects was unclear

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Vitamin D deficiency<br>serum 25(OH)D < 30 nmol/L | |
| Vitamin D insufficiency<br>serum 25(OH)D between 30 and 49 nmol/L | |
| Vitamin D sufficiency<br>serum 25(OH)D ≥ 50 nmol/L | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitamin D deficiency | Vitamin D deficiency (serum 25(OH)D < 30 nmol/L) | 1 minute after the survey (cross-sectional analysis) |
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Study Overview
=================
Brief Summary
-----------------
To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Official Title
-----------------
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Conditions
-----------------
ALCL

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies Clinical data registered in SFCE database Signed consent form Exclusion Criteria: No ALK expression on tumour No consent signed
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients treated for anaplastic large cell lymphoma ( ALCL )<br> | Other: Blood sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology |  | up to 78 months |
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

Detailed Description
-----------------
This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.

Official Title
-----------------
A Prospective Cohort Study of Immunoglobulin G (IgG) Dynamics Against SARS-Co

Conditions
-----------------
SARS-CoV-2 Acute Respiratory Disease

Intervention / Treatment
-----------------
* Other: SARS-CoV-2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Willing to provide informed consent prior to participation. Cohort 1 (Arm 1) - Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial Cohort 2 (Arm 2) - Received the COVID-19 vaccine Exclusion Criteria: Unable or unwilling to provide informed consent Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Unvaccinated SARS-CoV-2 positive<br>Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated | Other: SARS-CoV-2<br>* Observational<br>|
| Vaccinated<br>Participants who were vaccinated against SARS-CoV-2 | Other: SARS-CoV-2<br>* Observational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the longevity and seroprevalence of IgG against SARS-CoV-2 in a cohort of individuals exposed to SARS-CoV-2 |  | Up to 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the off-kinetics of IgG positivity against SARS-CoV-2, stratified by age, sex, race, ethnicity, infection symptomaticity, initial viral load |  | Up to 9 months | 
| To compare the off-kinetics of IgG positivity against SARS-CoV-2 by natural infection vs vaccination |  | Up to 9 months |
Acute Hemodynamic Changes During Paracentesis

Study Overview
=================
Brief Summary
-----------------
The aim of our study was to evaluate hemodynamic changes during routine paracentesis in tense ascites using non-invasive inert gas rebreathing.

Conditions
-----------------
Tense Ascites, Liver Cirrhosis

Intervention / Treatment
-----------------
* Procedure: routine therapeutic paracentesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: refractory tense ascites with indication for therapeutic paracentesis Exclusion Criteria: pregnancy inability to give inform consent inability to perform rebreathing maneuver

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with refractory tense ascites<br> | Procedure: routine therapeutic paracentesis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in cardiac output | prior to and after paracentesis | 30 minutes | 
| change in systemic vascular resistance | prior to and after paracentesis | 30 minutes |
Far Infrared Radiation Treatment for Diabetes

Study Overview
=================
Brief Summary
-----------------
A study to determine the use of far infrared (FIR) radiation for treatment of diabetes.

Detailed Description
-----------------
Diabetes mellitus is a disease in which glucose is not sufficiently metabolized. This results in high glucose levels in blood and glucose in the urine. Cells can starve because glucose is not being metabolized. Both types of diabetes can cause dangerous complications, including blindness, heart and blood vessel disease, and kidney failure. A decrease in circulation may eventually require the amputation of limbs. We are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby improving the health of the patients.

Official Title
-----------------
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Radiation: Far Infrared Radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with type 1 or type 2 diabetes Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br> | Radiation: Far Infrared Radiation<br>* Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure. |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thye 1 Diabetes, Type 2 Diabetes
Ghrelin - A Possible Opportunity to Improve Appetite

Study Overview
=================
Brief Summary
-----------------
The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.

Detailed Description
-----------------
Randomized study with follow up evaluations each month until preterminal state. Cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.

Official Title
-----------------
Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: Ghrelin
* Drug: Ghrelin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Weight loss Exclusion Criteria: Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A, 1<br>Ghrelin | Drug: Ghrelin<br>* High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.<br>|
| Active Comparator: A, 2<br>Ghrelin. | Drug: Ghrelin<br>* Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Food intake |  | June 2008 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ghrelin, Nutrition, Cancer patients, Survival
Statin Impact on Quality of Life in Cirrhotic Patients

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate the impact o0f statin on parents' related quality of life.

Detailed Description
-----------------
Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Official Title
-----------------
the Impact of Statin on Quality of Life in Cirrhotic Patients

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Drug: Atorvastatin 20mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cirrhosis adult both sex Exclusion Criteria: renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: PLACEBO<br> | Drug: Placebo<br>* placebo arm<br>|
| Active Comparator: statin<br> | Drug: Atorvastatin 20mg<br>* active arm<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| impact on patient related quality of life | change in chronic liver disease questionnare | 6 months |
Determine the Point of View of Society Society to Natural Orifice Surgeon

Study Overview
=================
Brief Summary
-----------------
200 participants' perception and acceptability of natural hole surgeon

Detailed Description
-----------------
100 participants health personnel 100 participants population two group's perception and acceptability of natural orifice surgeon

Official Title
-----------------
the Rate of Awareness and Acceptability of Natural Orifice Surgeon in Middle Eastern Society is Similar to Other Studies

Conditions
-----------------
Health, Subjective

Intervention / Treatment
-----------------
* Procedure: natural orifice surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all female (health personnel and population) Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: health personnel<br>natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population | Procedure: natural orifice surgery<br>* evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology<br>|
| Placebo Comparator: population<br>natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population | Procedure: natural orifice surgery<br>* evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| natural orifice surgery | a survey study that measures the awareness of natural orifice surgery | 12 months |
A Pan-Canadian, Retrospective Evaluation of MitraClip Safety and Efficacy

Study Overview
=================
Brief Summary
-----------------
The PREMISE Registry is a retrospective, observational study that will evaluate the efficacy and safety of the MitraClip in real-world Canadian practice. It will include all patients who have undergone MitraClip implantation in Canada to date.

Detailed Description
-----------------
In addition to evaluating efficacy and safety, PREMISE will include a description of patient demographics, etiology of mitral regurgitation, co-morbidities, medication use and functional class. It will also compare re-hospitalization for heart failure 12 months prior and 12 months after the procedure.

Official Title
-----------------
A Retrospective Multicenter Canadian Registry of Patients With Mitral Regurgitation Undergoing Percutaneous Mitral Valve Repair With MitraClip

Conditions
-----------------
Mitral Regurgitation

Intervention / Treatment
-----------------
* Device: MitraClip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has undergone percutaneous mitral valve repair with MitraClip Clip Delivery System in Canada Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MitraClip<br>All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada | Device: MitraClip<br>* Transcatheter Mitral Valve Repair with MitraClip<br>* Other names: MitraClip Clip Delivery System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mitral Regurgitation (MR) severity |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalization for Heart Failure |  | 12 months | 
| All-cause mortality |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MitraClip, Degenerative Mitral Regurgitation